As this is written ASTM is trading up $0.42 (23+%) at $2.21 after tagging $2.27 intraday on nearly 10 times the prior 3 months average daily volume – and the session isn’t over yet. The FDA granted Aastrom orphan drug status for its Tissue Repair cells bone marrow treatment. The key upside leve for this stock is the December 21, 2005 high of $2.53. A close above $2.38 would be a positive technical development with a close above $2.53 setting up a potetnial move to last summer’s July high are of $3.30-3.55. Above there the next key level is the 2005 high set in January above $4.30. Keep this one on your board!
